Serina Therapeutics to Present at the 38th Annual Roth Conference
Rhea-AI Summary
Serina Therapeutics (NYSE American: SER) announced that CEO Steve Ledger will present in a fireside chat at the 38th Annual Roth Conference in Dana Point, CA on March 24, 2026 at 11:30 a.m. PST.
A live webcast is available to registered attendees and an archived replay will be accessible on-demand for 90 days following the event.
Positive
- None.
Negative
- None.
News Market Reaction – SER
On the day this news was published, SER declined 22.86%, reflecting a significant negative market reaction. Argus tracked a peak move of +4.6% during that session. Argus tracked a trough of -21.7% from its starting point during tracking. Our momentum scanner triggered 51 alerts that day, indicating high trading interest and price volatility. This price movement removed approximately $10M from the company's valuation, bringing the market cap to $33.68M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
SER showed a strong move while momentum peers like BTAI (+2.72%) and GNTA (+2.33%) moved up modestly. Sector peers in the affinity list are mixed, suggesting the move is stock-specific rather than a broad biotechnology rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 18 | Private placement financing | Positive | +93.8% | Financing of up to $30M with warrant coverage to extend cash runway. |
| Feb 24 | Clinical dosing update | Positive | +6.0% | First patient dosed in Phase 1b registrational trial of SER-252. |
| Feb 19 | Clinical enrollment | Positive | +3.0% | First patient enrolled in Phase 1b registrational trial for SER-252. |
| Feb 03 | Investor presentation | Neutral | +1.5% | CEO webinar on FDA era and 2026 strategic priorities for investors. |
| Jan 28 | FDA IND clearance | Positive | +30.1% | FDA cleared IND for SER-252, enabling Phase 1b registrational study. |
Recent news with financings and clinical milestones has often coincided with positive price reactions.
Over the last few months, Serina reported multiple milestones around SER-252, including FDA IND clearance on Jan 28, 2026 and first patient enrollment and dosing updates in February, each followed by positive price reactions. A private placement for up to $30 million on Mar 18, 2026 saw a 93.75% move. Against this backdrop, the Roth conference appearance fits into an ongoing communications and funding cycle rather than a new clinical data event.
Regulatory & Risk Context
An effective S-3 dated 2026-01-30 registers 7,722,006 shares for resale tied to a 2025 senior unsecured convertible note and related warrants. The company will not receive proceeds from investors’ resales, but the underlying note provides up to $20 million of funding at 10% interest, convertible at $5.18 with warrants exercisable at $5.44 per share. The filing highlights going-concern, NYSE American equity notice, and early-stage clinical risks.
Market Pulse Summary
The stock dropped -22.9% in the session following this news. A negative reaction despite a simple conference announcement would fit a pattern where investors refocus on underlying financing and regulatory disclosures rather than non-data events. Recent history includes an effective S-3 registering 7,722,006 shares for resale and a private placement for up to $30 million, alongside going-concern and NYSE American equity risk factors, so sentiment could shift quickly back to balance-sheet and listing concerns.
AI-generated analysis. Not financial advice.
HUNTSVILLE, AL, March 24, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, announced that Steve Ledger, Chief Executive Officer, will present in a fireside chat at the 38th Annual Roth Conference in Dana Point, CA on March 24, 2026, at 11:30 a.m. PST.
A live webcast of the fireside chat style presentation will be accessible to registered attendees at this link. An archived replay will be available on-demand for 90 days following the event.
About Serina Therapeutics
Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina’s POZ Platform™ provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics, and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology. For more information, please visit https://www.serinatx.com/.
About the POZ Platform™
Serina's proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Serina's POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. The therapeutic agents in Serina's product candidates are typically well-understood and marketed drugs that are effective but are limited by pharmacokinetic profiles that can include toxicity, side effects and short half-life. Serina believes that by using POZ technology, drugs with narrow therapeutic windows can be designed to maintain more desirable and stable levels in the blood.
Serina's POZ platform delivery technology has potential for use across a broad range of payloads and indications. Serina intends to advance additional applications of the POZ platform via out-licensing, co-development, or other partnership arrangements, including the non-exclusive license agreement with Pfizer, Inc. to use Serina's POZ polymer technology for use in lipid nanoparticle drug (LNP) delivery formulations.
About SER-252 (POZ-apomorphine)
SER-252 is an investigational apomorphine therapy developed with Serina's POZ platform and designed to provide continuous dopaminergic stimulation (CDS). CDS has been shown to reduce the severity of levodopa-related motor complications (dyskinesia) in Parkinson's disease. Preclinical studies support the potential of SER-252 to provide CDS without skin reactions. For more information, please visit https://serinatx.com.
Cautionary Statement Regarding Forward-Looking Statement
This release contains forward-looking statements within the meaning of federal securities laws. All statements that are not historical fact, including statements about Serina's planned clinical programs, including timing for patient enrollment and dosing, the potential of Serina's POZ polymer technology, and the Company's ability to advance its clinical trial, are forward-looking statements that involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These statements are based on management's current expectations, plans, beliefs or forecasts for the future, and are subject to uncertainty and changes in circumstances. Undue reliance should not be placed on these forward-looking statements which speak only as of the date they are made, and the facts and assumptions underlying these statements may change.
Actual results may differ materially from those projected in such statements due to a variety of important factors including, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; Serina's ability to continue as a going concern; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when any applications may be filed for any drug or vaccine candidates in any jurisdictions; whether and when regulatory authorities may approve any potential applications that may be filed for any drug or vaccine candidates in any jurisdictions, which will depend on a myriad of factors, including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy and, if approved, whether any such drug or vaccine candidates will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of any drug or vaccine candidates; and competitive developments. These risks as well as other risks are more fully discussed in the company's Annual Report on Form 10-K for the year ended December 31, 2024, and the company's other periodic reports and documents filed from time to time with the SEC. The information contained in this release is as of the date hereof, and Serina assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
For inquiries, please contact:
Stefan Riley
sriley@serinatherapeutics.com
(256) 327-9630
FAQ
When will Serina Therapeutics (SER) present at the 38th Annual Roth Conference?
How can investors watch Serina Therapeutics (SER) CEO Steve Ledger at the Roth Conference?
Will Serina Therapeutics (SER) make the Roth Conference presentation available after March 24, 2026?
What format will Serina Therapeutics (SER) use for its Roth Conference presentation?
